microtubule affinity regulating kinase 1Genealiases: MARK · Par-1c · Par1c
Q-omics provides the consensus-scored MARK1 profile across patient tissues and cancer cell-line models. MARK1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MARK1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MARK1 protein abundance shows 32,401 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, HNSC, and GBM as cancer lineages where MARK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARK1 survival associations across molecular data types. MARK1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARK1 RNA expression–survival associations across cancer types. High MARK1 expression shows unfavorable associations in KICH, UVM, STAD and ACC, but favorable associations in PAAD and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MARK1 RNA expression.
This table summarizes MARK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MARK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARK1 shows lower tumor expression in THCA, KIRC and BRCA and higher tumor expression in HNSC, LUSC and CHOL. The HNSC box plot shows higher MARK1 RNA expression in tumor versus normal tissue (log2 FC = +1.795, t-test p < 0.001).
This table shows molecular features associated with MARK1 in patient tissues and cancer cell lines. In patient samples, MARK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MARK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
